ID   KMST-6
AC   CVCL_2998
SY   KMST6; Kawasaki Medical School Transformed-6
DR   BTO; BTO:0002039
DR   CLO; CLO_0050468
DR   BioSample; SAMN03471629
DR   BioSample; SAMN03472044
DR   IARC_TP53; 5358
DR   JCRB; JCRB0433
DR   RCB; RCB1955
DR   TKG; TKG 0482
DR   Wikidata; Q54900187
RX   CelloPub=CLPUB00712;
RX   DOI=10.11418/jtca1981.12.4_313;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=1537630;
RX   PubMed=2423124;
RX   PubMed=3140712;
RX   PubMed=3972471;
RX   PubMed=8105370;
RX   PubMed=8148305;
RX   PubMed=8557247;
RX   PubMed=8790940;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=19935656;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-172.html
CC   Population: Japanese.
CC   Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656).
CC   Doubling time: 38 +- 4.6 hours (Note=In 10% FBS), 54 +- 2.9 hours (Note=In 1% FBS) (PubMed=1537630); ~26 hours (Note=Lot 12242014) (JCRB=JCRB0433).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (PubMed=8790940).
CC   Transformant: NCIt; C129640; Cobalt-60 gamma radiation.
CC   Derived from site: In situ; Whole fetus; UBERON=UBERON_0000323.
CC   Cell type: Fibroblast; CL=CL_0000057.
ST   Source(s): JCRB; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,12 (JCRB)
ST   CSF1PO: 12 (RCB; TKG)
ST   D13S317: 10,11
ST   D16S539: 11
ST   D5S818: 10,12
ST   D7S820: 9
ST   TH01: 9
ST   TPOX: 11,12
ST   vWA: 14,18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2997 ! KMS-6
SX   Female
AG   9FW
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 26
//
RX   CelloPub=CLPUB00712;
RA   Henson J.D.;
RT   "The role of alternative lengthening of telomeres in human cancer.";
RL   Thesis PhD (2006), University of Sydney, Australia.
//
RX   DOI=10.11418/jtca1981.12.4_313;
RA   Namba M., Bai L., Kano Y., Sugihara S., Miyazaki M.;
RT   "Multistep malignant transformation of human cells: immortalization of
RT   human fibroblasts by treatment with 60Co gamma rays and 4-nitroquinoline
RT   1-oxide, and their malignant transformation with the ras oncogene.";
RL   Tissue Cult. Res. Commun. 12:313-318(1993).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=1537630; DOI=10.1002/ijc.2910500426;
RA   Mihara K., Bai L., Kano Y., Miyazaki M., Namba M.;
RT   "Malignant transformation of human fibroblasts previously immortalized
RT   with 60Co gamma rays.";
RL   Int. J. Cancer 50:639-643(1992).
//
RX   PubMed=2423124; DOI=10.1016/0304-419X(86)90001-6;
RA   Chang S.E.;
RT   "In vitro transformation of human epithelial cells.";
RL   Biochim. Biophys. Acta 823:161-194(1986).
//
RX   PubMed=3140712;
RA   Namba M., Nishitani K., Fukushima F., Kimoto T.;
RT   "Multistep carcinogenesis of normal human fibroblasts. Human
RT   fibroblasts immortalized by repeated treatment with Co-60 gamma rays
RT   were transformed into tumorigenic cells with Ha-ras oncogenes.";
RL   Anticancer Res. 8:947-958(1988).
//
RX   PubMed=3972471; DOI=10.1002/ijc.2910350221;
RA   Namba M., Nishitani K., Hyodoh F., Fukushima F., Kimoto T.;
RT   "Neoplastic transformation of human diploid fibroblasts (KMST-6) by
RT   treatment with 60Co gamma rays.";
RL   Int. J. Cancer 35:275-280(1985).
//
RX   PubMed=8105370; DOI=10.1128/mcb.13.10.6036-6043.1993;
RA   Ogata T., Ayusawa D., Namba M., Takahashi E., Oshimura M., Oishi M.;
RT   "Chromosome 7 suppresses indefinite division of nontumorigenic
RT   immortalized human fibroblast cell lines KMST-6 and SUSM-1.";
RL   Mol. Cell. Biol. 13:6036-6043(1993).
//
RX   PubMed=8148305;
RA   Namba M., Iijima M., Kondo T., Jahan I., Mihara K.;
RT   "Immortalization of normal human cells is a multistep process and a
RT   rate limiting step of neoplastic transformation of the cells.";
RL   Hum. Cell 6:253-259(1993).
//
RX   PubMed=8557247; DOI=10.1007/BF00218823;
RA   Sugihara S., Mihara K., Marunouchi T., Inoue H., Namba M.;
RT   "Telomere elongation observed in immortalized human fibroblasts by
RT   treatment with 60Co gamma rays or 4-nitroquinoline 1-oxide.";
RL   Hum. Genet. 97:1-6(1996).
//
RX   PubMed=8790940; DOI=10.1247/csf.21.111;
RA   Mihara K., Iijima M., Kondo T., Namba M.;
RT   "Selective expression of mutated p53 in human cells immortalized with
RT   either 4-nitroquinoline 1-oxide or 60Co gamma rays.";
RL   Cell Struct. Funct. 21:111-116(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=19935656; DOI=10.1038/nbt.1587;
RA   Henson J.D., Cao Y., Huschtscha L.I., Chang A.C.-M., Au A.Y.M.,
RA   Pickett H.A., Reddel R.R.;
RT   "DNA C-circles are specific and quantifiable markers of
RT   alternative-lengthening-of-telomeres activity.";
RL   Nat. Biotechnol. 27:1181-1185(2009).
//